HK1201747A1 - Chitosan covalently linked with small molecule integrin antagonist for targeted delivery - Google Patents

Chitosan covalently linked with small molecule integrin antagonist for targeted delivery

Info

Publication number
HK1201747A1
HK1201747A1 HK15102355.8A HK15102355A HK1201747A1 HK 1201747 A1 HK1201747 A1 HK 1201747A1 HK 15102355 A HK15102355 A HK 15102355A HK 1201747 A1 HK1201747 A1 HK 1201747A1
Authority
HK
Hong Kong
Prior art keywords
small molecule
covalently linked
targeted delivery
integrin antagonist
molecule integrin
Prior art date
Application number
HK15102355.8A
Other languages
English (en)
Chinese (zh)
Inventor
Jayne Chin
Jr Robert Alan Goodnow
Matthew Michael Hamilton
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1201747A1 publication Critical patent/HK1201747A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
HK15102355.8A 2012-01-27 2015-03-09 Chitosan covalently linked with small molecule integrin antagonist for targeted delivery HK1201747A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261591293P 2012-01-27 2012-01-27
US201261670665P 2012-07-12 2012-07-12
PCT/EP2013/051279 WO2013110681A1 (en) 2012-01-27 2013-01-24 Chitosan covalently linked with small molecule integrin antagonist for targeted delivery

Publications (1)

Publication Number Publication Date
HK1201747A1 true HK1201747A1 (en) 2015-09-11

Family

ID=47603735

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102355.8A HK1201747A1 (en) 2012-01-27 2015-03-09 Chitosan covalently linked with small molecule integrin antagonist for targeted delivery

Country Status (12)

Country Link
US (3) US20130197205A1 (xx)
EP (1) EP2806896B1 (xx)
JP (1) JP6230199B2 (xx)
KR (1) KR20140120316A (xx)
CN (1) CN104039356B (xx)
BR (1) BR112014015753A8 (xx)
CA (1) CA2854251A1 (xx)
DK (1) DK2806896T3 (xx)
HK (1) HK1201747A1 (xx)
MX (1) MX2014008404A (xx)
RU (1) RU2014132564A (xx)
WO (1) WO2013110681A1 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9447035B2 (en) * 2012-01-27 2016-09-20 Hoffmann-La Roche Inc. Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4
SG11201600379TA (en) 2013-08-07 2016-02-26 Arrowhead Res Corp Polyconjugates for delivery of rnai triggers to tumor cells in vivo
CN112969687A (zh) 2018-10-30 2021-06-15 吉利德科学公司 作为α4β7整合素抑制剂的喹啉衍生物
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CA3115830C (en) 2018-10-30 2023-09-12 Gilead Sciences, Inc. Compounds for inhibition of .alpha.4.beta.7 integrin
KR102641718B1 (ko) 2018-10-30 2024-02-29 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 이미다조피리딘 유도체
CN114222730A (zh) 2019-08-14 2022-03-22 吉利德科学公司 用于抑制α4β7整合素的化合物
CN115073311B (zh) * 2022-03-23 2023-05-23 河南大学 一种高效制备n,n′-二（2羟乙基）苯胺的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US622901A (en) * 1899-04-11 Machine for making tufted fabrics
US5486140A (en) 1993-10-21 1996-01-23 Venturedyne, Ltd. Variable air volume terminal unit with exterior insulation
SE9402528D0 (sv) 1994-07-19 1994-07-19 Astra Ab Hårdvävnadsstimulerande med el
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
US6380387B1 (en) 1999-12-06 2002-04-30 Hoffmann-La Roche Inc. 4-Pyrimidinyl-n-acyl-l phenylalanines
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
US7875449B2 (en) 2006-09-15 2011-01-25 Fmc Biopolymer As Oligonucleotide non-viral delivery systems
KR100825519B1 (ko) * 2007-01-05 2008-04-25 주식회사 바이오폴리메드 키토산 기재 고분자 접합체 및 그 제조방법
US20110033547A1 (en) 2007-07-06 2011-02-10 Aarhus Universitet Dehydrated chitosan nanoparticles
US20100272813A1 (en) 2007-07-23 2010-10-28 Aarhus Universitet Nanoparticle-mediated treatment for inflammatory diseases
CN101293933B (zh) * 2008-06-17 2011-05-04 浙江大学 聚乙二醇修饰壳寡糖脂肪酸嫁接物及制备方法和应用
EP2350043B9 (en) 2008-10-09 2014-08-20 TEKMIRA Pharmaceuticals Corporation Improved amino lipids and methods for the delivery of nucleic acids
US20120040004A1 (en) * 2009-01-28 2012-02-16 Region Midtjylland Treatment of radiation-induced fibrosis

Also Published As

Publication number Publication date
EP2806896B1 (en) 2018-01-03
DK2806896T3 (en) 2018-03-05
US20180099005A1 (en) 2018-04-12
CN104039356A (zh) 2014-09-10
US20150306130A1 (en) 2015-10-29
RU2014132564A (ru) 2016-03-20
BR112014015753A8 (pt) 2017-07-04
US20130197205A1 (en) 2013-08-01
EP2806896A1 (en) 2014-12-03
US11491178B2 (en) 2022-11-08
BR112014015753A2 (pt) 2017-06-13
WO2013110681A1 (en) 2013-08-01
MX2014008404A (es) 2014-08-22
JP6230199B2 (ja) 2017-11-15
CN104039356B (zh) 2018-08-17
JP2015504958A (ja) 2015-02-16
CA2854251A1 (en) 2013-08-01
KR20140120316A (ko) 2014-10-13

Similar Documents

Publication Publication Date Title
IL268420A (en) Oligonucleotide conjugates
EP2723393A4 (en) EXTRACELLULAR TARGETED CONSTITUENT CONJUGATES
HK1201747A1 (en) Chitosan covalently linked with small molecule integrin antagonist for targeted delivery
HK1207388A1 (en) Self-stabilizing linker conjugates
HK1205928A1 (en) Ocular drug delivery system
IL235608A (en) Carriers for improved drug delivery
GB201215193D0 (en) Order delivery system
BR112014015195A2 (pt) Artigo de entrega de fluxo
EP2896022A4 (en) DRUG ADMINISTRATION REGULATOR
EP2683328A4 (en) ADMINISTRATION SYSTEM
EP2793953A4 (en) TELODENDRIMERS WITH INCREASED DRUG DELIVERY
GB201121069D0 (en) Delivery system
BR112013028570A2 (pt) nanopartículas poliméricas para administração de fármacos
EP2818140A4 (en) STENT DELIVERY SYSTEM
EP2624798A4 (en) ARTICLE COMPRISING A BENEFICIAL AGENT DISTRIBUTION SYSTEM FOR HEALTH
EP2683737A4 (en) EXTRACELLULAR TARGETED CONSTITUENT CONJUGATES
GB201217493D0 (en) Delivery receptacles
ZA201309156B (en) Drug delivery system
EP2670780A4 (en) CELLULOSE-BASED NANOPARTICLES FOR DRUG DELIVERY
IL235363A0 (en) Means for releasing pesticides
SG10201609440WA (en) Multi-additive delivery system
PL2908837T3 (pl) Kompozycje do dostarczania leku
EP2896401A4 (en) TARGETED ACTIVE AGGREGATION SYSTEM FOR HEAVY-DUTY ACTIVE SUBSTANCE
EP2852378A4 (en) COPOLYMER-XEROGEL NANOCOMPOSITES USEFUL FOR THE ADMINISTRATION OF MEDICAMENTS
ES1076172Y (es) Cierre para vehiculo de reparto